Cargando…

Efficacy of Conversion Surgery Following Apatinib Plus Paclitaxel/S1 for Advanced Gastric Cancer With Unresectable Factors: A Multicenter, Single-Arm, Phase II Trial

Objective: Conversion therapy (surgical resection after chemotherapy) is a promising option for unresectable gastric cancer (GC) patients. Addition of anti-angiogenesis drug improves response to chemotherapy. Hence, this study explored the feasibility and efficacy of preoperative paclitaxel (PTX)/S1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Zhiyuan, Hu, Can, Yu, Jianfa, Du, Yian, Hu, Ping, Yu, Guofa, Hu, Conggang, Zhang, Yu, Mao, Wei, Chen, Shanqi, Cheng, Xiangdong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8017219/ https://www.ncbi.nlm.nih.gov/pubmed/33815124 http://dx.doi.org/10.3389/fphar.2021.642511

Ejemplares similares

Apatinib enhances chemosensitivity of gastric cancer to paclitaxel and 5-fluorouracil
por: Xu, Zhiyuan, et al.
Publicado: (2019)

Case report: Long-term partial response of apatinib plus paclitaxel as second-line therapy in a patient with metastatic gastric cancer
por: Fu, Shengya, et al.
Publicado: (2022)

Sintilimab combined with apatinib plus capecitabine in the treatment of unresectable hepatocellular carcinoma: A prospective, open-label, single-arm, phase II clinical study
por: Li, Dailong, et al.
Publicado: (2022)

Transcatheter arterial chemoembolization plus apatinib with or without camrelizumab for unresectable hepatocellular carcinoma: a multicenter retrospective cohort study
por: Duan, Xuhua, et al.
Publicado: (2023)

Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Apatinib Compared with Conventional Transarterial Chemoembolization Plus Apatinib in the Treatment of Unresectable Hepatocellular Carcinoma
por: Zhang, Weihua, et al.
Publicado: (2021)

Apatinib treatment for unresectable gastrointestinal stromal tumor with synchronous gastric cancer
por: Xu, Huanji, et al.
Publicado: (2020)

Conversion surgery with gemcitabine plus nab-paclitaxel for locally advanced unresectable pancreatic cancer: A case report
por: Okura, Ryosuke, et al.
Publicado: (2018)

Efficacy and Safety of Apatinib in Treatment of Unresectable Intrahepatic Cholangiocarcinoma: An Observational Study
por: Hu, Yubin, et al.
Publicado: (2020)

Efficacy and Safety of Apatinib in Advanced Hepatocellular Carcinoma: A Multicenter Real World Retrospective Study
por: Zheng, Zhuangzhuang, et al.
Publicado: (2022)

Efficacy and safety of apatinib alone or apatinib plus paclitaxel/docetaxel versus paclitaxel/docetaxel in the treatment of advanced non‐small cell lung cancer: A meta‐analysis
por: Li, Zhe, et al.
Publicado: (2021)

Apatinib Combined With SOX Regimen in Conversion Treatment of Advanced Gastric Cancer: A Case Series and Literature Review
por: Jiang, Dingyi, et al.
Publicado: (2020)

CYP2D6 gene polymorphism and apatinib affect the metabolic profile of fluvoxamine
por: Ye, Zhize, et al.
Publicado: (2022)

Camrelizumab Plus Apatinib in Treatment-Naive Patients With Advanced Nonsquamous NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 2 Trial
por: Ren, Shengxiang, et al.
Publicado: (2022)

Short-term survival and safety of apatinib combined with oxaliplatin and S-1 in the conversion therapy of unresectable gastric cancer
por: Ye, Zaisheng, et al.
Publicado: (2021)

Efficacy and Safety of Apatinib for the Treatment of Advanced or Recurrent Cervical Cancer: A Single-Arm Meta-Analysis Among Chinese Patients
por: Huang, Da, et al.
Publicado: (2022)

Combination of pembrolizumab plus temozolomide therapy in unresectable and advanced melanoma: a multicenter retrospective analysis in China
por: Hu, Tu, et al.
Publicado: (2021)

An exploratory clinical trial of apatinib combined with intensity‐modulated radiation therapy for patients with unresectable hepatocellular carcinoma
por: Qiu, Hu, et al.
Publicado: (2022)

Transarterial chemoembolization plus apatinib with or without camrelizumab for unresected hepatocellular carcinoma: A two-center propensity score matching study
por: Zhu, Di, et al.
Publicado: (2022)

Comparing the effectiveness and safety of Sorafenib plus TACE with Apatinib plus TACE for treating patients with unresectable hepatocellular carcinoma: a multicentre propensity score matching study
por: Yin, Liang, et al.
Publicado: (2023)

Apatinib combined with paclitaxel-based chemotherapy in patients with taxane-resistant advanced gastric cancer: a single-arm exploratory study
por: Zhao, Shen, et al.
Publicado: (2020)

Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial
por: Lan, Chunyan, et al.
Publicado: (2020)

Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial
por: Zhang, Wenwen, et al.
Publicado: (2023)

Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study
por: Mao, Lili, et al.
Publicado: (2022)

Application of physiologically-based pharmacokinetic/pharmacodynamic models to evaluate the interaction between nifedipine and apatinib
por: Liu, Hongrui, et al.
Publicado: (2022)

Application of Physiologically Based Pharmacokinetic Modeling to Evaluate the Drug–Drug and Drug–Disease Interactions of Apatinib
por: Liu, Hongrui, et al.
Publicado: (2021)

Androgen deprivation therapy plus apalutamide as neoadjuvant therapy prior radical prostatectomy for patients with unresectable prostate cancer
por: Wei, Yongbao, et al.
Publicado: (2023)

Camrelizumab Plus Apatinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: An Open-Label, Single-Arm, Phase II Study
por: Ding, Xi, et al.
Publicado: (2023)

Comparison of D2 and D2 plus radical surgery for advanced distal gastric cancer: a randomized controlled study
por: Yu, Pengfei, et al.
Publicado: (2019)

Apatinib in patients with recurrent or metastatic thymic epithelial tumor: a single-arm, multicenter, open-label, phase II trial
por: Song, Zhengbo, et al.
Publicado: (2022)

Late combination of transarterial chemoembolization with apatinib and camrelizumab for unresectable hepatocellular carcinoma is superior to early combination
por: Ju, Shuguang, et al.
Publicado: (2022)

The role of apatinib combined with paclitaxel (aluminum binding type) in platinum-resistant ovarian cancer
por: Zhao, Hong, et al.
Publicado: (2020)

Avatrombopag for the treatment of thrombocytopenia induced by chemotherapy in patients with solid tumors: A multicenter, open-label, single-arm trial
por: Cui, Yayun, et al.
Publicado: (2022)

Apatinib for recurrent/progressive glioblastoma multiforme: A salvage option
por: Zhang, Hong-Hong, et al.
Publicado: (2022)

Effect of X-ray radiation on the pharmacokinetics of apatinib in vivo in rats
por: Dong, Shi-Qi, et al.
Publicado: (2022)

Multicenter phase II study of Apatinib in non-triple-negative metastatic breast cancer
por: Hu, Xichun, et al.
Publicado: (2014)

Adjuvant albumin-bound paclitaxel combined with S-1 vs. oxaliplatin combined with capecitabine after D2 gastrectomy in patients with stage III gastric adenocarcinoma: a phase III multicenter, open-label, randomized controlled clinical trial protocol
por: Cheng, Xiangdong, et al.
Publicado: (2021)

Case report: Apatinib combined with neoadjuvant therapy for primary squamous cell carcinoma of the breast: a case report
por: Gao, Fangfang, et al.
Publicado: (2023)

A single-arm, prospective study of apatinib mesylate plus pemetrexed in patients of advanced non-squamous non-small cell lung cancer after failure of previous chemotherapy
por: Dong, Shuang, et al.
Publicado: (2022)

Sintilimab Plus Bevacizumab Biosimilar Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
por: Peng, Ye, et al.
Publicado: (2022)

Apatinib Plus Temozolomide: An Effective Salvage Treatment for Recurrent Glioblastoma
por: Ge, Jingjing, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vefefimet7apgmb5ur60upp46n